CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 36 enrolled
Drug / intervention
RO7126209 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04023994
NCT04023994Phase 1Completed
CompareCT.gov

A Single-Center, Randomized, Adaptive, Investigator/Subject Blind, Single Ascending Dose, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

Hoffmann-La Roche·interventional·Posted Jul 18, 2019·Updated Aug 9, 2021

In Brief

A Phase 1 clinical trial evaluating RO7126209 and Placebo for Alzheimers Disease. Completed, enrolled 36 participants across 1 site.

Detailed Summary

Study BP41192 is a randomized, adaptive, placebo-controlled parallel group study to investigate the safety, tolerability, immunogenicity and pharmacokinetics of single-ascending intravenous (IV) doses of RO7126209 in healthy participants. RO7126209 is being developed for the treatment of Alzheimer's Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimers Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJul 18, 2019
Enrollment StartAug 3, 2019
Primary CompletionJul 17, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.0 years ago

Interventions

RO7126209drug

Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.

Placebodrug

Participants will be administered a single intravenous dose of matching placebo.